Scavenging effects of terbinafine on free radicals in vitro

Camera, Emanuela; Cannistraci, Carlo Vittorio; Briganti, Stefania; Colombo, Diego; Picardo, Mauro

doi:10.1046/j.1365-2133.1999.02762.x

Cited by 15 publications

(16 citation statements)

References 11 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An individual susceptibility to SD appears to exist and may be due related to the presence of high levels of proinflammatory cytokines that which have been found in the normal skin of SD patients (26). The efficacy of terbinafine may therefore be due to its additional properties, such as the antiinflammatory effects (8)(9)(10)(11). Moreover, a recent study has shown that oral terbinafine inhibits lipid peroxidation and can modulate sebum composition in vivo (27).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Oral Terbinafine in the Treatment of Multi-Site Seborrheic Dermatitis: A Multicenter, Double-Blind Placebo-Controlled Study

Micali

Santoianni

et al. 2005

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Seborrheic dermatitis (SD) is a common disorder for which no satisfactory curative treatment exists. Preliminary studies suggest that terbinafine may be effective. The efficacy and tolerability of oral terbinafine was evaluated in multi-site SD in a randomized, double-blind, placebo-controlled study. For this purpose, 174 adult patients with SD lesions involving ::::3 skin areas, each causing ::::2 moderate/severe symptoms according to a pre-defined clinical score, were classified according to the localization oflesions: patients with lesions predominantly involving non-exposed skin areas, such as scalp and hairline and sternum and/or interscapular area (population A, n=83) or patients with lesions in exposed sites, mainly the face (population B, n=91). Patients were randomized to oral terbinafine (250 mg/day) (n=86) or matching placebo (n=88), each given for 6 weeks. Primary efficacy variable was the response rate, defined as :::50% decrease in baseline total clinical score without rescue medication intake after 6 weeks of treatment. The main secondary assessments were: subject's global assessment of relief and proportion of patients satisfied with treatment. Recurrence rate was assessed in responder patients during a 4-week treatment-free period. In Population A the response rate after 6 weeks oftreatment was significantly higher with terbinafine (70% vs 45.4%; p=0.03) and so was the proportion of patients who reported relief (75% vs 41%; p=0.007) and who were satisfied (66% vs 40%; p=0.02). No significant differences were recorded in Population B. Adverse events occurred in 11.5% of terbinafine patients and 8% of placebo patients. One patient discontinued treatment with terbinafme because of adverse events (mild tachycardia and insomnia). In conclusion, our results show that terbinafine is significantly more effective than placebo in reducing the severity of SD lesions in nonexposed sites. Clinical trials comparing terbinafine to standard treatment regimens in different types of patients with SD are warranted.Seborrheic dermatitis (SD) IS a common eczematous skin disorder that affects 1-3% of immunocompetent adults (1). There are still controversies over the pathogenesis of this inflammatory condition: both qualitative and quantitative abnormalities of sebum, as well as overgrowth of lipophilic yeasts of Malassezia genus (mainly Pityrosporum ova/e) and associated inflammatory reactions may play a role in the development of symptoms and signs of SD (2). Current treatment of SD is symptomatic rather than curative. It includes topical corticosteroids which can be used only for short periods of time because of the risk of side effects, such as skin atrophy and telangiectasias. More recently, antifungal agents have been introduced (1,3).Terbinafine is an allylamine antimycotic agent that has been proposed for the treatment of SD.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The drug also possesses immunomodulatory, antioxidant and antiinflammatory properties (8)(9)(10)(11). It is highly lipophilic and is distributed widely in the body; very high concentrations of terbinafine have been found in the skin and appendages, where the drug persists for 2-3 weeks after discontinuation of treatment (12).…”

mentioning

confidence: 99%

Oral Terbinafine in the Treatment of Multi-Site Seborrheic Dermatitis: A Multicenter, Double-Blind Placebo-Controlled Study

Micali

Santoianni

et al. 2005

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

show abstract

“…Terbinafine has an anti-inflammatory action, probably linked to the scavenging properties of the molecule, but this action has only been observed in vitro [61,62]. Terbinafine has also demonstrated anti-Malassezia spp.…”

Section: Terbinafinementioning

confidence: 99%

Seborrhoeic dermatitis: current treatment practices

Gupta

Kogan

2004

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Seborrhoeic dermatitis (SD) is a recurrent, chronic inflammation of the skin that occurs on sebum rich areas such as the face, scalp and chest, characterised by red scaly lesions. The are many studies indicating that Malassezia yeasts play an important role in the aetiology of this condition, most of the evidence for which comes from demonstrated responsiveness to treatment with antifungal agents. Its aetiology, however, is far from being resolved. Some believe that it is the immune response of the skin to the Malassezia that is the cause of the disease. Traditional treatments of SD have been the use of keratolytic agents or corticosteroids. Since the discovery of ketoconazole, a considerable amount of research has been focused on determining the efficacy of various antifungal agents. This article reviews clinical trial data on treatment options available for SD.

show abstract

“…Seborrhoeic dermatitis (SD) is a common skin disease found in 1–3% of the general population. Considerable importance has been attributed to microbiological, especially mycotic, 1 causes of this affection, and over the past few years various studies have underlined the effectiveness of antifungal products. However, substances with an anti‐inflammatory action but without antifungal effects have also proved to be particularly effective 2 .…”

mentioning

confidence: 99%

“…However, substances with an anti‐inflammatory action but without antifungal effects have also proved to be particularly effective 2 . Preliminary in vitro studies have emphasized the anti‐inflammatory properties of the antifungal agent terbinafine, 1,3–5 in particular the drug's antioxidant properties seem to have an important role. SD is characterized by a condition of oxidative stress that leads to an increase in lipoperoxidation that is responsible for altering the composition of sebum, as well as producing inflammation mediators 6,7 …”

mentioning

confidence: 99%